Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Oslo – page 2

534 clinical trials in Oslo, Norway across 9 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Oslo at a glance
534
clinical trials
  • Research sites9
Type of trial
Recruitment status
Quick filters

534 trials in Oslo

Open in trial search

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.

Narcolepsy

Recruiting

Study on the Long-term Safety of TAK-861 for Patients with Narcolepsy Type 1

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.

Coeliac disease

Recruiting

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
  • Sponsor:Dr. Falk Pharma GmbH

Squamous cell carcinoma of head and neck

Recruiting

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Colorectal cancer metastatic

Recruiting

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Neoplasm malignant

Recruiting

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Neoplasm malignant

Recruiting

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Type 1 diabetes mellitus

Recruiting

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Type 1 diabetes mellitus

Recruiting

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Chronic graft versus host disease

Recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Oslo

What the registry says about research in the country

01 Respiratory Medicine

Clinical trials focusing on pulmonary conditions and respiratory health, including studies on idiopathic pulmonary fibrosis and respiratory syncytial virus prevention in children.

  • IPF Treatment Evaluation
  • RSV Prevention Studies
  • Chronic Wet Cough Research

Innovative therapies being tested to improve lung function and patient outcomes.

02 Cardiovascular Research

Studies examining heart conditions and vascular health, with particular focus on heart failure and cardiovascular disease prevention.

  • Heart Failure Imaging Studies
  • Cardiovascular Disease Prevention
  • Hypovolemia Management

Advanced imaging techniques and therapeutic interventions being evaluated for cardiac conditions.

03 Oncology Studies

Comprehensive research into various cancer treatments, including trials for gastric, esophageal, and rare cancers.

  • Advanced Solid Tumors
  • Targeted Cancer Therapies
  • Multiple Myeloma Treatment

Novel therapeutic approaches combining immunotherapy with conventional treatments.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.